Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer

Baumgart, Juliane; Nilsson, Kerstin; Evers, Anneli Stavreus; Kallak, Theodora Kunovac; Sundström‐Poromaa, Inger

doi:10.1097/gme.0b013e31826560da

Cited by 141 publications

(88 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Emerging data suggest that although both selective estrogen receptor modulators (e.g., tamoxifen) and the aromatase inhibitors (AIs) may affect sexual function, the risk to sexual health may be greater with the AIs. This was shown in a study by Baumgart et al in which more than 80 women taking tamoxifen or an AI were compared with women without breast cancer (controls) [37]. Among women taking an AI, significantly higher rates of sexual dysfunction were reported compared with both those taking tamoxifen and controls in the area of lubrication issues (74% vs. 40% and 42%, respectively), dyspareunia (57% vs. 31% and 21%), and global dissatisfaction with their sex lives (42% vs. 17.8% and 14%).…”

Section: Medical Therapymentioning

confidence: 97%

Sexual Health as a Survivorship Issue for Female Cancer Survivors

2014

View full text Add to dashboard Cite

As more and more people are successfully treated for and live longer with cancer, greater attention is being directed toward the survivorship needs of this population. Women treated for cancer often experience issues related to sexual health and intimacy, which are frequently cited as areas of concern, even among long-term survivors. Unfortunately, data suggest that providers infrequently discuss these issues. We reviewed a contemporary understanding of sexual health of women and the impact of treatment on both sexual function and intimacy.

show abstract

Section: Medical Therapymentioning

confidence: 97%

Sexual Health as a Survivorship Issue for Female Cancer Survivors

2014

View full text Add to dashboard Cite

show abstract

“…There is increasing awareness of the prevalence of genitourinary side effects of endocrine therapy and their potential impact on sexual functioning [Chin et al 2009;Baumgart et al 2013;Baumgart et al 2011;Schover et al 2006;Donovan, 2012]. It has been reported that up to 50-75% of breast cancer survivors experience one or more genitourinary symptoms [Ganz et al 1998;Trinkaus et al 2008].…”

Section: Introductionmentioning

confidence: 99%

A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy

et al. 2017

View full text Add to dashboard Cite

There is increasing attention and concern about managing the adverse effects of adjuvant endocrine therapy for women with early breast cancer as the side effects of therapy influence compliance and can impair quality of life (QoL). Most side effects associated with tamoxifen (TAM) and aromatase inhibitors (AIs) are directly related to estrogen deprivation, and the symptoms are similar to those experienced during natural menopause but appear to be more severe than that seen in the general population. Prolonged estrogen deprivation may lead to atrophy of the vulva, vagina, lower urinary tract and supporting pelvic structures, resulting in a range of genitourinary symptoms that can in turn lead to pain, discomfort, impairment of sexual function and negatively impact on multiple domains of QoL. The genitourinary side effects may be prevented, reduced and managed in most cases but this requires early recognition and appropriate treatment. We provide an overview of practical clinical approaches to understanding the pathophysiology and the management of genitourinary symptoms in postmenopausal women receiving adjuvant endocrine therapy for breast cancer.

show abstract

“…Sexual sequelae from aromatase inhibitors can be severe and debilitating (vaginal, vulvar, and/or clitoral dryness). 129 Management can include reinforcing and encouraging nonpenetrative sex if non-estrogen vaginal products to ease dyspareunia are insufficient.…”

Section: Radiation Chemotherapy and Hormonal Considerationsmentioning

confidence: 99%